Assessment of effect of irbesartan and nebivolol on the left atrium volume and deformation in the patients with mild-moderate hypertension

ArticleAçık Erişim

Özet

BACKGROUND: We aimed to assess the effects of irbesartan and nebivolol on the left atrium (LA) volume and deformation in the patients with mild-moderate hypertension. PATIENTS AND METHODS: The study comprised of 160 patients (mean age: 55.6±9.6 years), who had Stage 1 or 2 hypertension according to the European Society of Cardiology (ESC) and have not been receiving antihypertensive therapy.The patients were assigned to treatment groups; irbesartan (n=80) and nebivolol (n=80). The patients were clinically and echocardiographically reevaluated on the 6th and 12th months after the onset of treatment. RESULTS: There was no difference between the two treatment groups in terms of baseline demographic, clinical and echocardiographic characteristics. Moreover, no difference was observed between the treatment groups on the 6th and 12th months. Intragroup analyses revealed that systolic blood pressure (SBP) and diastolic blood pressure (DBP) significantly decreased in time and diastolic function parameters were improved. However, whilst significant increase was observed in conduit volume, decrease was observed in other volumes of the LA in the irbesartan and nebivolol groups. This significant change was observed on the 6th month in both treatment groups. LA global peak systolic strain (LAGLSs), LA global peak systolic strain rate (LAGLSRs), LA global peak strain rate during early ventricular diastole (LAGLSRe) and LA global peak strain rate (LAGLSRa) during late ventricular diastole (LAGLSRa) values began to be significantly increased after 6 months of treatment in both treatment groups. CONCLUSIONS: We found that nebivolol, which is a new generation beta blocker, is effective as irbesartan with proven efficacy in improving LA volume and LA myocardial performance in patients with mild-moderate hypertension. Moreover, we determined that strain and strain rate, which are the new echocardiographic parameters, are effective as LA volumes in assessing LA functions.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/15753Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorDegirmenci, H.
dc.contributor.authorDuman, H.
dc.contributor.authorDemirelli, S.
dc.contributor.authorBakirci, E.M.
dc.contributor.authorHamur, H.
dc.contributor.authorInci, S.
dc.contributor.authorSimsek, Z.
dc.contributor.authorAskin, L.
dc.contributor.authorArisoy, A.
dc.contributor.authorLazoglu, Z.
dc.date.accessioned2026-10-18T20:30:35.985209718Z
dc.date.available2026-10-18T20:30:35.985209718Z
dc.date.issued2014
dc.description.abstractBACKGROUND: We aimed to assess the effects of irbesartan and nebivolol on the left atrium (LA) volume and deformation in the patients with mild-moderate hypertension. PATIENTS AND METHODS: The study comprised of 160 patients (mean age: 55.6±9.6 years), who had Stage 1 or 2 hypertension according to the European Society of Cardiology (ESC) and have not been receiving antihypertensive therapy.The patients were assigned to treatment groups; irbesartan (n=80) and nebivolol (n=80). The patients were clinically and echocardiographically reevaluated on the 6th and 12th months after the onset of treatment. RESULTS: There was no difference between the two treatment groups in terms of baseline demographic, clinical and echocardiographic characteristics. Moreover, no difference was observed between the treatment groups on the 6th and 12th months. Intragroup analyses revealed that systolic blood pressure (SBP) and diastolic blood pressure (DBP) significantly decreased in time and diastolic function parameters were improved. However, whilst significant increase was observed in conduit volume, decrease was observed in other volumes of the LA in the irbesartan and nebivolol groups. This significant change was observed on the 6th month in both treatment groups. LA global peak systolic strain (LAGLSs), LA global peak systolic strain rate (LAGLSRs), LA global peak strain rate during early ventricular diastole (LAGLSRe) and LA global peak strain rate (LAGLSRa) during late ventricular diastole (LAGLSRa) values began to be significantly increased after 6 months of treatment in both treatment groups. CONCLUSIONS: We found that nebivolol, which is a new generation beta blocker, is effective as irbesartan with proven efficacy in improving LA volume and LA myocardial performance in patients with mild-moderate hypertension. Moreover, we determined that strain and strain rate, which are the new echocardiographic parameters, are effective as LA volumes in assessing LA functions.
dc.identifier.endpage789
dc.identifier.issn1128-3602
dc.identifier.issue6
dc.identifier.pmid24706300
dc.identifier.scopus2-s2.0-84902106827
dc.identifier.startpage781
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/15753
dc.identifier.volume18
dc.identifier.wosWOS:000341968400004
dc.language.isoen
dc.publisherVerduci Editore
dc.relation.ispartofEuropean Review for Medical and Pharmacological Sciences
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectIrbesartan
dc.subjectLeft atrial function
dc.subjectNebivolol
dc.subjectAntihypertensive Agents
dc.subjectBenzopyrans
dc.subjectBiphenyl Compounds
dc.subjectBlood Pressure
dc.subjectDiastole
dc.subjectEchocardiography
dc.subjectEthanolamines
dc.subjectFemale
dc.subjectHeart Atria
dc.subjectHumans
dc.subjectHypertension
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectProspective Studies
dc.subjectSystole
dc.subjectTetrazoles
dc.subjectantihypertensive agent
dc.subjectbenzopyran derivative
dc.subjectbiphenyl derivative
dc.subjectethanolamine derivative
dc.subjecttetrazole derivative
dc.subjectadult
dc.subjectantihypertensive therapy
dc.subjectarticle
dc.subjectcardiovascular parameters
dc.subjectcohort analysis
dc.subjectcontrolled clinical trial
dc.titleAssessment of effect of irbesartan and nebivolol on the left atrium volume and deformation in the patients with mild-moderate hypertension
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus17
rdl.citation.wos15
rdl.departmentDepartment of Cardiology, Erzincan University, Erzincan, Turkey. demirelli23@yahoo.com.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)